📰 Collective Coordinates News
Page 5 - Collective Coordinates News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Collective Coordinates. Real-time updates on events, politics, business and more.
May 13, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
April 21, 2022
Science 37 (NASDAQ:SNCE – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Analyst Recommendations This is a breakdown of current recommendations […]
April 18, 2022
/PRNewswire/ -- Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN)...
March 25, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares MaxCyte and ProMIS Neurosciences’ net margins, […]
January 27, 2022
27.01.2022 - TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins ...
October 22, 2021
Expanded management team to lead development programs with special focus on PMN310 for Alzheimer's diseaseTORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:
October 22, 2021
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics
August 12, 2021
TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) ("ProMIS or the Company"), a biotechnology company focused on the discovery and development
May 25, 2021
ProMIS Neurosciences Inc.: ProMIS Neurosciences initiates commercialization of COVID-19 serology assay Seasoned industry executive and entrepreneur, Owen Dempsey to lead the effort for ProMIS TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, ...
May 21, 2021
PMN310 potential best in class antibody candidate for treatment of Alzheimer's diseaseTORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF)